ArticleImmunity, inflammation and disease2026
Clinical Feasibility and Safety of Nasal Allergen Provocation Testing in Pediatric Allergic Rhinitis.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "Clinical Feasibility and Safety of Nasal Allergen Provocation Testing in Pediatric Allergic Rhinitis".Immunity, inflammation and disease · 2026Article
- Clinical Feasibility and Safety of Nasal Allergen Provocation Testing in Pediatric Allergic Rhinitis.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNasal allergen provocation testing (NAPT) has been shown to be a safe and reproducible test in adults; however, pediatric data are limited. This study aims to investigate the clinical applications, feasibility, reproducibility and safety of NAPT in the pediatric population. MATERIAL AND
methodsIn this prospective study, 294 patients (4.16-14.25 years old, mean of 7.33 years), with symptoms and medical history of allergic rhinitis (AR) and IgE-mediated sensitization to Dermatophagoides pteronyssinus and Dermatophagoides farinae were recruited. Participants underwent NAPT with negative control and with increasing concentrations of crude Dermatophagoides farinae (50 µg/ml, 500 µg/ml, and 5000 µg/ml) at 15 min intervals. Pre- and post-test subjective symptom scores and objective active anterior rhinometry measurements were analyzed.
resultsAmong the 245 participants (83.3%) with a positive NAPT, the majority (n = 193, 78.8%) tested positive at 500 µg/ml or less. They (n = 226, 92.2%) were diagnosed based on an increase in total nasal symptoms score (TNSS) ≥ 5 points. The remaining 7.8% (n = 19) required objective measurements to fulfill the criteria for a positive result. Five participants were unable to fully comply with the instructions provided. There were no adverse events recorded during the study. The group which tested positive on NAPT recorded higher sIgE levels than that which tested negative. Furthermore, those with higher serum sIgE levels tested positive on NAPT at lower allergen concentrations. The baseline visual analog scale (VAS) was significantly higher in the group testing positive on NAPT at the lowest allergen concentration, compared with the other groups.
conclusionOur study demonstrates that NAPT is safe and feasible to be conducted on the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.